Company intelligence / Profile preview

Atridia Pty Ltd

Sydney, New South Wales, Australia

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Atridia has several approved drugs in China including IL-17A inhibitors (approved August 20, 2024), PDL1 inhibitors (approved February 28, 2023), and AR antagonists (approved June 28, 2022). Their drug Adebrelimab is marketed for small cell lung cancer and in Phase III for non-small cell lung cancer.

Therapeutic areas: GastroenterologyOncologyHematology
Modalities: Monoclonal antibodyAntibody drug conjugate (ADC)Bispecific antibodyAntibody fusion proteinsSmall molecule drug
Industry: Biotech

Drug pipeline

2 assets

SHR0410

1 more asset in the full pipeline.

Request access →

Partnerships

Jiangsu Hengrui Medicine Co., Ltd.

Beyond the preview

Go deeper on Atridia Pty Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atridia Pty Ltd.

Explore the full profile